Previous 10 | Next 10 |
Data from a Phase 2 study in congenital hyperinsulinism (CHI) shared at ENDO 2019 and a budget impact model presented at AMCP reinforce the utility of Xeris’ ready-to-use, liquid-stable glucagon Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leve...
Dosing is underway in a Phase 2 clinical trial evaluating Xeris Pharmaceuticals' (NASDAQ: XERS ) ready-to-use, room temperature-stable liquid glucagon in type 1 diabetics who experience exercise-induced hypoglycemia. More news on: Xeris Pharmaceuticals, Inc., Healthcare stocks news, ...
Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that it has now begun dosing patients in a Phase 2 trial with its rea...
Xeris Pharmaceuticals ( XERS ) is developing a resolution to a major dilemma in the diabetic population using their exclusive technologies for the delivery of ready-to-use, room temperature stable formulations. Although Xeris is a recent IPO , the company's researchers have been hard at w...
Xeris Pharmaceuticals (NASDAQ: XERS ): Q4 GAAP EPS of -$0.98 misses by $0.25 . More news on: Xeris Pharmaceuticals, Earnings news and commentary, Healthcare stocks news, Read more ...
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end 2018; February 2019 public offering raised additional $55.6 million to support...
Self-respect--the secure feeling that no one, as yet, is suspicious .” ― H.L. Mencken We start a new weekly feature today here at The Insiders Forum. Every week we will be providing very brief overviews of five interesting stocks insiders are currently buying. I have always ...
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that on February 27, 201...
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize ready-to-use injectable and infusible drug formulations, today announced that Paul R. Edick, Chair...
Motif Bio (NASDAQ: MTFB ) -75% on receiving CRL from FDA. More news on: Motif Bio, Inovio Pharmaceuticals, Inc., Sierra Wireless, Inc., Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
Xeris Pharmaceuticals Inc. Company Name:
XERS Stock Symbol:
NASDAQ Market:
Conference call and webcast at 8:30am ET Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that the C...
John Shannon, President and Chief Operating Officer, to succeed Paul Edick as new CEO and Board Director Transition timing aligns with the solid financial position of the Company, including consistently strong growth from its commercial franchise, healthy cash position, and the track reco...
Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of therapies, today announced that on July 1, 2024, the Compensation Committee of Xeris’ Boar...